Core Insights - Okogen Inc. has acquired the global intellectual property portfolio and development assets for ranpirnase from Orgenesis Inc., enhancing its lead ophthalmic program and laying the groundwork for expansion into additional antiviral indications [1][7]. Company Overview - Okogen Inc. is a biotechnology company focused on developing antiviral therapeutics targeting ocular infections, respiratory viruses, and emerging infectious diseases. Its lead candidate, OKG-0303, is aimed at treating acute infectious conjunctivitis [4]. Ranpirnase Details - Ranpirnase is a ribonuclease enzyme that disrupts viral replication by degrading intracellular RNA, creating a bottleneck in viral protein production. This mechanism offers a differentiated approach to antiviral development, potentially reducing resistance seen with traditional antivirals. Ranpirnase has been evaluated in clinical trials with over 1,000 patients, providing substantial safety and translational data for further development [5]. Development Strategy - The company is prioritizing the rapid advancement of its ranpirnase program, OKG-0303, which addresses a fragmented treatment landscape for acute infectious conjunctivitis. Okogen is also exploring ranpirnase as a potential antiviral countermeasure against high-consequence pathogens like Marburg and Sudan viruses, while conducting parallel research on respiratory viruses such as influenza and RSV [7].

Company Overview - Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing oral antiviral therapies for serious viral diseases [3] - The company has developed a proprietary nucleos(t)ide prodrug platform aimed at treating single-stranded ribonucleic acid (ssRNA) viruses, which are a significant cause of serious viral infections [3] - Atea's lead program is in global Phase 3 development, focusing on a combination regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, specifically targeting Hepatitis C Virus (HCV) [3] Upcoming Events - Members of Atea's management team will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025, at 1:05 p.m. ET in New York [1] - A live webcast of the presentation will be available on the company's website, with an archived version accessible for at least 90 days following the event [2]